HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

L Andries Selected Research

R 306465

11/2007R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


L Andries Research Topics

Disease

2Neoplasms (Cancer)
11/2017 - 11/2007
1Squamous Cell Carcinoma of Head and Neck
11/2017
1Fistula
07/2012
1Gastroesophageal Reflux (GERD)
07/2012
1Lymphoma (Lymphomas)
11/2007
1Carcinoma (Carcinomatosis)
11/2007
1Prostatic Neoplasms (Prostate Cancer)
11/2007

Drug/Important Bio-Agent (IBA)

1Biomarkers (Surrogate Marker)IBA
11/2017
1AntibodiesIBA
11/2017
1imgatuzumabIBA
11/2017
1Cetuximab (Erbitux)FDA Link
11/2017
1benzamideIBA
07/2012
14- bromo- N- (1- (2,4- difluoro- phenyl)ethyl)- 2- (quinoxaline- 5- sulfonylamino)benzamideIBA
07/2012
1AcidsIBA
07/2012
1Cholecystokinin (Pancreozymin)IBA
07/2012
1Histamine (Histamine Dihydrochloride)FDA Link
07/2012
1Pentagastrin (Peptavlon)FDA Link
07/2012
1QuinoxalinesIBA
07/2012
1Histones (Histone)IBA
11/2007
1R 306465IBA
11/2007
1Histone Deacetylase InhibitorsIBA
11/2007
1Histone Deacetylases (Histone Deacetylase)IBA
11/2007

Therapy/Procedure

1Oral Administration
11/2007